Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Preclinical CRO Market Research Report by Services (Bioanalysis and DMPK Studies and Toxicology Testing), End-user, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Preclinical CRO Market size was estimated at USD 4,925.16 million in 2021, USD 5,379.95 million in 2022, and is projected to grow at a CAGR 9.55% to reach USD 8,517.42 million by 2027.
Market Segmentation & Coverage:
This research report categorizes the Preclinical CRO to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Services, the market was studied across Bioanalysis and DMPK Studies and Toxicology Testing.
- Based on End-user, the market was studied across Biopharmaceutical Companies, Government and Academic Institutes, and Medical Device Companies.
- Based on Application, the market was studied across Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Immunological Disorders, Infectious Diseases, Oncology, and Respiratory Diseases.
- Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Minnesota, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Preclinical CRO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.
Market Dynamics
Drivers
- Rise in Spending on CRO Services
- Surge in the Number of Drugs in the Preclinical Phase
- Increasing Support and Approval Processes from Regulatory Authorities Related to Cro Services
Restraints
- Lack of Standardization as Per International Regulatory Requirements
Opportunities
- Increase in R&D Budget for Drug Development
- Growing Trend of Outsourcing End-To-End Services by Pharmaceutical Companies
Challenges
- High Adoption Rate Toxicology Testing
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Preclinical CRO Market, by Services
7. Preclinical CRO Market, by End-User
8. Preclinical CRO Market, by Application
9. Americas Preclinical CRO Market
10. Asia-Pacific Preclinical CRO Market
11. Europe, Middle East & Africa Preclinical CRO Market
12. Competitive Landscape
13. Company Usability Profiles
14. Appendix
Companies Mentioned
- Atuka Inc.
- CATO SMS
- Celerion
- Charles River Laboratories International, Inc.
- Emergo
- Ethica Group
- Eurofins Scientific
- ICON PLC
- Inotiv, Inc.
- Laboratory Corporation of America, Inc.
- Medpace, Inc.
- PharmaCircle LLC
- PPD Inc.
- SCiAN Services
- Shanghai Medicilon Inc.
- Syneos Health, Inc.
- Syreon Corporation
- Veristat LLC
- Vimta Labs Limited
- WuXi AppTec, Inc.
- ZM Company
For more information about this report visit https://www.researchandmarkets.com/r/b6f8iv
Attachment
